Protara Therapeutics (TARA)
(Delayed Data from NSDQ)
$1.79 USD
+0.03 (1.70%)
Updated Oct 4, 2024 04:00 PM ET
After-Market: $1.79 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
D Value C Growth B Momentum C VGM
Brokerage Reports
0 items in cart
Protara Therapeutics, Inc. [TARA]
Reports for Purchase
Showing records 1 - 20 ( 20 total )
Company: Protara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Positive Ahead of ADVANCED-2 Update in 2H24; Reit Buy and $23 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Protara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Key Upcoming Catalyst Looks at Six-Month Evaluable Patients From ADVANCED-2 in 2H24
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Protara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
TARA-002 is Here to Stay in NMIBC, While IV Choline Program Gets Positive FDA Feedback
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Protara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Steady Updates From ADVANCED NMIBC Trials, Makes For Attractive Point of Entry; Reit Buy and $23 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Protara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Incremental ADVANCED-1 Update Continues to Trend Positive
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Protara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
TARA-002?s Position in NMIBC Remains Positive; Reit. Buy and $23 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Protara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Dynamics Catalysts Across the Urothelial Cancer Landscape
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Protara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
TARA-002 Continues Its Assault Against NMIBC, Data in 1H24; Reit. Buy and $23 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Protara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Positive Peak At TARA-002?s Efficacy Is Just the Beginning; Reit. Buy and $23 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Protara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ADVANCED-1 Reports Early Positive Efficacy For TARA-002 in NMIBC; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Protara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ADVANCED-1 Data in 2Q23 Looks to Put TARA-002 On the Map in NMIBC; Reit. Buy and $23 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Protara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Bladder Cancer KOL Dinner Highlights-Innovations, Inconsistencies and Experimentation Shape the UC Landscape
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Protara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
TARA-002?s Progress Evident on All Fronts; Reit Buy and $23 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Protara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
ADVANCE-1 Remains Key Value Driver; Reit. Buy and Lowering our PT to $23
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Protara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Protara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Track to Tackle BCG Shortage; Reit. Buy and $40 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Protara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
On Track to Initiate TARA-002 in NMIBC by YE21; Reiterate Buy and $40PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Protara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Protara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
TARA-002 Phase 1 Initiation and GMP Scale up Expected by YE21; Reit Buy and $40PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Protara Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
A De-Risked Rare Disease Asset Which Holds Substantial Play in Oncology: Initiating With Buy and $40 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
|